25I-NBOMe: Difference between revisions
>Unity m Split reference list. |
>Unity m Grammatics |
||
Line 2: | Line 2: | ||
{{SummarySheet}} | {{SummarySheet}} | ||
{{SubstanceBox/25I-NBOMe}} | {{SubstanceBox/25I-NBOMe}} | ||
'''25I-NBOMe''' (also known as '''2C-I-NBOMe''', '''Cimbi-5''' and '''N-Bomb''', although this term is also commonly referred to other members of the [[25x-NBOMe]] family) is novel synthetic [[Psychoactive class::psychedelic]] of the [[chemical class::phenethylamine]] chemical class. It produces | '''25I-NBOMe''' (also known as '''2C-I-NBOMe''', '''Cimbi-5''' and '''N-Bomb''', although this term is also commonly referred to other members of the [[25x-NBOMe]] family) is novel synthetic [[Psychoactive class::psychedelic]] of the [[chemical class::phenethylamine]] chemical class. It produces an array of visual-dominant [[psychedelic]] and prominent [[stimulating]] effects when [[Routes of administration|administered]]. | ||
The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-I]]. It first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin,<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> and subsequently investigated by a team at Purdue University led by psychedelics chemist and researcher [[David E. Nichols]] as a research tool to map out the [[serotonin]] receptor system.<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> | The name 25I-NBOMe, which short-hand for 2C-I-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-I]]. It first synthesized and documented in 2003 by Ralf Heim at the Free University of Berlin,<ref name="Ralf Heim PhD. (2010-02-28)">Ralf Heim PhD. (2010-02-28) "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts." | http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> and subsequently investigated by a team at Purdue University led by psychedelics chemist and researcher [[David E. Nichols]] as a research tool to map out the [[serotonin]] receptor system.<ref name="Michael Robert Braden PhD. (2007)">Michael Robert Braden PhD. (2007). "Towards a biophysical understanding of hallucinogen action." | http://proquest.umi.com/pqdlink?Ver=1&Exp=01-23-2014&FMT=7&DID=1417800971&RQT=309&attempt=1&cfc=1 Purdue University. Retrieved 2012-08-08.</ref> | ||
Line 8: | Line 8: | ||
It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family are not [[orally]] active and should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. 25I-NBOMe can also be vaporized and inhaled; this is known to cause significantly more rapid and powerful effects and a shorter duration. However, this route of administration is heavily advised against due to the difficulties of measuring and handling substances that both have a low [[therapeutic index]] and are also active in the microgram range. | It is worth noting that compounds of the [[25x-NBOMe|NBOMe]] family are not [[orally]] active and should be administered [[sublingual|sublingually]] by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes. 25I-NBOMe can also be vaporized and inhaled; this is known to cause significantly more rapid and powerful effects and a shorter duration. However, this route of administration is heavily advised against due to the difficulties of measuring and handling substances that both have a low [[therapeutic index]] and are also active in the microgram range. | ||
In comparison to [[2C-I]], the addition of an NBOMe group to the structure results in a sixteen-fold increase in potency, allowing even the heaviest of dosages to fit in liquid form onto tabs and blotter paper, which are often misrepresented or mistaken for [[LSD]]. In contrast to LSD, 25i-NBOMe has a distinctly bitter and metallic taste that numbs the location of the mouth it is applied to. This property is often used as a makeshift test for its authenticity but is generally advised against. Users instead are encouraged to test all of their blotters through a drug testing service or with the appropriate | In comparison to [[2C-I]], the addition of an NBOMe group to the structure results in a sixteen-fold increase in potency, allowing even the heaviest of dosages to fit in liquid form onto tabs and blotter paper, which are often misrepresented or mistaken for [[LSD]]. In contrast to LSD, 25i-NBOMe has a distinctly bitter and metallic taste that numbs the location of the mouth it is applied to. This property is often used as a makeshift test for its authenticity but is generally advised against. Users instead are encouraged to test all of their blotters through a drug testing service or with the appropriate reagent testing kit due to the hazards this substance can pose. | ||
This substance had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}} Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans, and has been associated with many deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood [[psychedelic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it. | This substance had no history of human use before being sold online as a [[designer drug]] in 2010.{{citation needed}} Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25I-NBOMe in humans, and it has been associated with many deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood [[psychedelic]] substance with the proper amount of precaution and [[Responsible drug use#Hallucinogens|harm reduction practices]] if choosing to use it. | ||
==Chemistry== | ==Chemistry== |